openPR Logo
Press release

Global Cancer ALK Inhibitor Market || Keyplayers Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc. and Xcovery.

04-12-2021 04:35 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Prophecy Market Insights

Prophecy Market Insights

Prophecy Market Insights

The Global Cancer ALK Inhibitor Market accounted for US$ 2.96 million in 2020 and is estimated to be US$ 23.1 million by 2030 and is anticipated to register a CAGR of 20%. ALK inhibitors are anti-cancer drugs that acts on tumors with variations of anaplastic lymphoma kinase such as EML4-ALK translocation and falls in the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in abnormal growth of tumor cells. All the ALK inhibitors present today in the market function by binding to ATP pocket of abnormal ALK protein, blocking its access to energy and deactivating it.

The report " Global Cancer ALK Inhibitor Market, By Drug (Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena)), By Type (First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

Global Phase III clinical trial (eXalt3) is going on comparing Ensartinib to Crizotinib in TKI nave ALK positive patient. Primary purpose for this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive.
Xcovery is investigating drug candidate, Ensartinib which is best-in-class oral compound for first-line treatment of ALK-positive NSCLC.
Analyst View:

Increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market. Many key players are coming with new drugs and new technologies. Various organizations such as W.H.O., FEAT, and others along with the government are spreading awareness about this syndrome condition which is anticipated to facilitate market growth in the forecast period.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Cancer ALK Inhibitor Market, By Drug (Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena)), By Type (First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Cancer-ALK-Inhibitor-Market-4665

Key Market Insights from the report:

The Global Cancer ALK Inhibitor Market accounted for US$ 2.96 million in 2020 and is estimated to be US$ 23.1 million by 2030 and is anticipated to register a CAGR of 20%. The Global Cancer ALK Inhibitor Market is segmented based on the Drug, Type, Distribution Channel and region.

By Drug, the Global Cancer ALK Inhibitor Market is segmented into Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena).
By Type, the market is segmented in First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors.
By Distribution Channel, the Global Cancer ALK Inhibitor Market is segmented into Hospital pharmacies, Online Pharmacies and Others.
By region, the Global Cancer ALK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Competitive Landscape:

The key players operating in the Global Cancer ALK Inhibitor Market include AstraZeneca Plc

Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc..

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period
Key Topics Covered

Introduction
Study Deliverables
Study Assumptions
Scope of the Study
Research Methodology
Executive Summary
Opportunity Map Analysis
Market at Glance
Market Share (%) and BPS Analysis, by Region
Competitive Landscape
Heat Map Analysis
Market Presence and Specificity Analysis
Investment Analysis
Competitive Analysis
To know more

Contact Us:

Sales

Prophecy Market Insights

1 860 531 2701

Email- sales@prophecymarketinsights.com

Contact Us:
Mr Alex (Sales Manager)
Prophecy Market Insights
Phone: +91 777 504 9802
+1 860 531 2701
Email: sales@prophecymarketinsights.com

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer ALK Inhibitor Market || Keyplayers Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc. and Xcovery. here

News-ID: 2269082 • Views: 201

More Releases from Prophecy Market Insights

Global Robotics Surgical Simulation Systems Market is estimated to be US$ 2178.2 …
The Global Robotics Surgical Simulation Systems Market accounted for US$ 464.8 million in 2020 and is estimated to be US$ 2178.2 million by 2030 and is anticipated to register a CAGR of 16.9%. Robotics surgical simulation systems are the advance technology which holds lots of potentials to transfigure the surgical education practices. The developments in computational technologies amplified by the immeasurable knowledge of the functioning of the human body have
Global Cell and Gene Therapy Market worth US$ 1.8 billion 2019 with a CAGR of 35 …
The report "Global Cell and Gene Therapy Market, By Products (Cell Therapy, and Gene Therapy), By Distribution Channel Type (Oncology, Dermatology, Musculoskeletal, and Others), By End-Users (Hospitals, Wound Care Centers, Cancer Care Centers, Ambulatory Surgical Centers, and Others), and Region - Global Forecast to 2030" global cell and gene therapy market is projected to grow from US$ 1.8 billion in 2019. The major factor driving the global cell and gene
Global Food Flavor Market is estimated to be US$ 27.7 Bn by 2030 with a CAGR of …
The significant growth of the food flavor market is increasing due to consumer gaining interest towards purchasing clean label goods, which offers wide scope for sources with natural ingredients. Interest in ethnic or exotic flavors is one of the key drivers of the food flavor market. The report "Global Food Flavor Market, By Form (Liquid, Dry, Gas), By Type (Natural, Synthetic), By Flavor Ingredients (Alcoholic Note Flavor, Cocoa, Berries, coffee, citrus,
Global Jaundice Meter Market–Analysis and Demand with Forecast Overview to 203 …
The global jaundice meter market accounted for US$ 85 million in 2020 and is estimated to be US$ 108.3 million by 2030 and is anticipated to register a CAGR of 2.5%. The report "Global Jaundice Meter Market, By Type (Portable, and Bench-top), By Application (Hospital, and Home), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2030”. Key Highlights: In

All 5 Releases


More Releases for ALK

Epinephrine Market 2017 - Pfizer, Mylan, Sanofi, ALK Abello, Hospira
Apex Market Reports, recently published a detailed market research study focused on the "Epinephrine Market" across the global, regional and country level. The report provides 360° analysis of "Epinephrine Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Epinephrine industry, and estimates the future trend of Epinephrine market on the basis of
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
GLOBAL EPINEPHRINE AUTOINJECTOR MARKET- MYLAN, SANOFI, ALK, ABELLO, IMPAX
Global Industry Study Evaluate on Epinephrine Autoinjector Market by Type, Manufacturers, Regions, and Application, Forecast up to 2022 The scope of the Epinephrine Autoinjector Report: This report primarily focuses on Epinephrine Autoinjector in the global market. This report generally covers Epinephrine Autoinjector market in North America, Epinephrine Autoinjector market in Asia-Pacific, Epinephrine Autoinjector market in Europe, Epinephrine Autoinjector market in Latin America, Middle as well as Africa. This report partitions the Epinephrine